189 related articles for article (PubMed ID: 37681568)
1. Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease.
Welty FK; Hariri E; Asbeutah AA; Daher R; Amangurbanova M; Chedid G; Elajami TK; Alfaddagh A; Malik A
J Am Heart Assoc; 2023 Sep; 12(18):e030071. PubMed ID: 37681568
[TBL] [Abstract][Full Text] [Related]
2. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
Alfaddagh A; Elajami TK; Ashfaque H; Saleh M; Bistrian BR; Welty FK
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246960
[TBL] [Abstract][Full Text] [Related]
3. An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment.
Alfaddagh A; Elajami TK; Saleh M; Mohebali D; Bistrian BR; Welty FK
Atherosclerosis; 2019 Jun; 285():153-162. PubMed ID: 31055222
[TBL] [Abstract][Full Text] [Related]
4. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
[TBL] [Abstract][Full Text] [Related]
5. Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial.
Hariri E; Asbeutah AA; Malik A; Amangurbanova M; Chedid G; Daher R; Al Hammoud M; Welty FK
Atherosclerosis; 2023 Dec; 387():117388. PubMed ID: 38056242
[TBL] [Abstract][Full Text] [Related]
6. Effect of Eicosapentaenoic Acid/Docosahexaenoic Acid on Coronary High-Intensity Plaques Detected Using Noncontrast T1-weighted Imaging: The AQUAMARINE EPA/DHA Randomized Study.
Nakao K; Noguchi T; Miura H; Asaumi Y; Morita Y; Takeuchi S; Matama H; Sawada K; Doi T; Hosoda H; Nakashima T; Honda S; Fujino M; Yoneda S; Kawakami S; Nagai T; Nishihira K; Kanaya T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Kusano K; Yamamoto H; Omae K; Ogawa H; Yasuda S
J Atheroscler Thromb; 2024 Feb; 31(2):122-134. PubMed ID: 37704431
[TBL] [Abstract][Full Text] [Related]
7. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Nakao K; Noguchi T; Asaumi Y; Morita Y; Kanaya T; Fujino M; Hosoda H; Yoneda S; Kawakami S; Nagai T; Nishihira K; Nakashima T; Kumasaka R; Arakawa T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Yamamoto H; Hamasaki T; Yasuda S
Trials; 2018 Jan; 19(1):12. PubMed ID: 29310688
[TBL] [Abstract][Full Text] [Related]
8. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
9. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
[TBL] [Abstract][Full Text] [Related]
10. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
[TBL] [Abstract][Full Text] [Related]
11. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.
Lu MT; Ribaudo H; Foldyna B; Zanni MV; Mayrhofer T; Karady J; Taron J; Fitch KV; McCallum S; Burdo TH; Paradis K; Hedgire SS; Meyersohn NM; DeFilippi C; Malvestutto CD; Sturniolo A; Diggs M; Siminski S; Bloomfield GS; Alston-Smith B; Desvigne-Nickens P; Overton ET; Currier JS; Aberg JA; Fichtenbaum CJ; Hoffmann U; Douglas PS; Grinspoon SK;
JAMA Cardiol; 2024 Apr; 9(4):323-334. PubMed ID: 38381407
[TBL] [Abstract][Full Text] [Related]
12. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
13. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
[TBL] [Abstract][Full Text] [Related]
14. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoprotein cholesterol, triglycerides, and characteristics of coronary atherosclerosis in patients with significant coronary artery disease newly diagnosed by computed tomography coronary angiography.
Oleksiak A; Kępka C; Rucińska K; Marcinkiewicz K; Demkow M; Kruk M
Kardiol Pol; 2023; 81(3):273-280. PubMed ID: 36475513
[TBL] [Abstract][Full Text] [Related]
16. Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology - A Serial Computed Tomography Angiography Study.
Motoyama S; Nagahara Y; Sarai M; Kawai H; Miyajima K; Sato Y; Matsumoto R; Takahashi H; Naruse H; Ishii J; Ozaki Y; Izawa H
Circ J; 2022 Apr; 86(5):831-842. PubMed ID: 34776470
[TBL] [Abstract][Full Text] [Related]
17. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
[TBL] [Abstract][Full Text] [Related]
18. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B
Welty FK; Schulte F; Alfaddagh A; Elajami TK; Bistrian BR; Hardt M
FASEB J; 2021 Apr; 35(4):e21448. PubMed ID: 33749913
[TBL] [Abstract][Full Text] [Related]
19. Exercise Capacity, Coronary Artery Fatty Plaque, Coronary Calcium Score, and Cardiovascular Events in Subjects With Stable Coronary Artery Disease.
Malik A; Kanduri JS; Asbeutah AAA; Khraishah H; Shen C; Welty FK
J Am Heart Assoc; 2020 Apr; 9(7):e014919. PubMed ID: 32212910
[TBL] [Abstract][Full Text] [Related]
20. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
